Test Price
2,800 AED✅ Home Collection Available
TPRN Gene Sequencing (DFNB79) – Autosomal Recessive Deafness 79 Genetic Test in UAE
Executive Summary & Core Metrics
TPRN gene sequencing (DFNB79) delivers definitive molecular confirmation for congenital or early‑onset profound deafness via high‑coverage Next‑Generation Sequencing. This test enables precise recurrence risk counselling, cochlear implant candidacy assessment, and early intervention planning for families across the UAE.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO‑certified genomic processing and triple‑validated variant calling.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection available daily from 8 AM to 11 PM across all Emirates.
- Clinical Guidance: Complimentary post‑test telephonic interpretation session by a Consultant Medical Geneticist (Arabic & English).
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731 – we handle pre‑approval with Daman, AXA, Neuron, and more.
Test Overview & Methodology
This targeted sequencing assay reads the entire coding region and ±10 base‑pair flanking intronic boundaries of the TPRN gene using high‑depth Next‑Generation Sequencing on the Illumina NovaSeq platform. Mean on‑target depth exceeds 500×, ensuring robust detection of single‑nucleotide variants, small insertions, and deletions responsible for DFNB79 autosomal recessive deafness. Results are interpreted by a Consultant Medical Geneticist and aligned with UAE National Newborn Hearing Screening Programme guidelines.
| Feature | Our Test (Depth & Compliance) | Closest Alternative (Basic Panel) |
|---|---|---|
| Methodology | High‑coverage NGS (Illumina NovaSeq) with >500× mean on‑target depth | Low‑plex Sanger sequencing or untargeted exome |
| Clinical Specificity | 100% for TPRN‑only coding + splice sites ±10 bp | May miss deep intronic or regulatory variants |
| Turnaround Time | 3–4 weeks (dry‑lab validation included) | 6–8 weeks uncertainty |
| UAE Regulatory Clearance | DHA/MOHAP‑notified lab, ISO 9001:2015 certified | Often no local accreditation |
| Post‑test Support | Board‑certified clinical geneticist session included | Report only, no counselling |
Physician Insight & Safety Protocols
“Every TPRN result must be weighed alongside the child’s audiogram, developmental trajectory, and family pedigree. A negative sequencing report does not eliminate all hereditary deafness possibilities; if clinical suspicion persists, I advise complementary copy‑number variant analysis and a follow‑up genetics consultation. My team supports each family from sample collection through result interpretation — you are never alone in this journey.” — Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
⚠️ Important Advisory – Medication & Clinical Caution
Do not discontinue any prescribed therapy, including diuretics or anticoagulants, without explicit instruction from your treating physician. Genetic testing is an elective diagnostic tool and does not replace emergency audiological care for sudden hearing loss, vertigo, or focal neurologic symptoms.
Exclusion Criteria & ER Red Flags
- Exclusion: Patients below 18 years without legal guardian consent (as per Federal Decree‑Law No. 4 of 2016 on Medical Liability). Active febrile illness or ongoing systemic infection may delay blood draw; reschedule when afebrile for optimal sample quality.
- Do NOT wait for genetic results if you experience: Sudden acute hearing loss with vertigo, tinnitus, or focal weakness – seek immediate ER evaluation. Genetic testing is elective and not intended for emergency diagnosis.
- Safety Barrier: Post‑test, incidental findings of uncertain significance will be communicated via the ordering physician only, in accordance with UAE health information governance.
Patient FAQ & Clinical Guidance
1. What is the TPRN gene test and how does it help my family?
This test reads the entire coding sequence of the TPRN gene using high‑depth Next‑Generation Sequencing to identify recessive mutations responsible for DFNB79 hereditary deafness. It confirms the genetic cause, estimates recurrence risk for siblings and future children, and guides cochlear implant candidacy decisions under the supervision of a Consultant Medical Geneticist.
2. Is a blood sample absolutely necessary, or can I use a simple cheek swab?
A single blood draw (3–5 mL in EDTA tube) or a dried blood spot on an FTA card is required because DNA yield from saliva or buccal swabs often falls below the 100 ng input threshold essential for high‑depth NGS, which could compromise variant detection sensitivity. Our VIP Mobile Phlebotomy service ensures convenient home collection with full cold‑chain integrity.
3. Will my health insurance cover the 2,800 AED cost for this test?
Most UAE insurers cover hereditary hearing loss genetic testing when accompanied by a referral letter from an ENT consultant stating medical necessity. Our billing team will verify your policy via WhatsApp +971 54 548 8731 and obtain direct approval before the blood draw, so you pay only any remaining co‑insurance. We handle pre‑approval with Daman, AXA, Neuron, and other major networks.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE operates under DHA Facility License Number 1143 and complies fully with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) for all genetic data processing, storage, and sharing. All clinical health information is additionally governed by Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient consent for genetic testing and sample handling follows the requirements of Federal Decree‑Law No. 4 of 2016 on Medical Liability. Our laboratory is ISO 9001:2015 certified and regularly audited by Dubai Health Authority for compliance with genomic medicine best practices.
Clinical & Logistical Metadata
| Test Name | TPRN Gene Sequencing (DFNB79) – Autosomal Recessive Deafness 79 |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Whole blood (EDTA tube) or dried blood spot (FTA card) – 3–5 mL |
| Methodology Used | Next‑Generation Sequencing (Illumina NovaSeq) >500× on‑target depth |
| ICD-10-CM Code | H90.3 (Sensorineural hearing loss, bilateral) |
| LOINC Code | 55233-1 |
| DHA Facility License & Address | License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians